health benefits of glp-1 agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 receptor agonists for weight

Retatrutide (Triple GLP-1R/GIPR/GCGR agonist (LY3437943)) is a 39-amino acid triple-receptor peptide

In the ELIXA trial, Pfeffer et al 27 evaluated the effect of lixisenatide in patients with type 2 diabetes with myocardial infarction or unstable angina admission in the previous 180 days

Some plans cover these medications but only for patients with specific comorbidities like diabetes, heart disease, or sleep apnea

The salt paradox and its possible implications in managing hypertensive diabetic patients

Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: A multicenter prospective observational study

Insulin secretion deficits in a Prader-Willi syndrome -cell model are associated with a concerted downregulation of multiple endoplasmic reticulum chaperones